Titan Medical Inc. (NASDAQ:TMDI) has received an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy rating.
Brokers have set a 1 year consensus target price of $5.33 for the company and are expecting that the company will post ($0.61) EPS for the current quarter, according to Zacks. Zacks has also given Titan Medical an industry rank of 77 out of 256 based on the ratings given to its competitors.
A number of equities analysts have issued reports on the stock. ValuEngine raised shares of Titan Medical from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research lowered shares of Titan Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, August 13th. Piper Jaffray Companies assumed coverage on shares of Titan Medical in a research report on Wednesday, May 22nd. They set an “overweight” rating and a $6.00 price target for the company. Finally, Northland Securities reissued a “buy” rating on shares of Titan Medical in a research report on Thursday, July 18th.
A hedge fund recently raised its stake in Titan Medical stock. Valeo Financial Advisors LLC grew its position in Titan Medical Inc. (NASDAQ:TMDI) by 4,411.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 45,117 shares of the company’s stock after buying an additional 44,117 shares during the period. Valeo Financial Advisors LLC owned 0.21% of Titan Medical worth $106,000 at the end of the most recent quarter. 13.29% of the stock is currently owned by hedge funds and other institutional investors.
TMDI stock traded down $0.16 during trading on Friday, reaching $2.06. The company had a trading volume of 303,000 shares, compared to its average volume of 298,252. The firm has a 50-day simple moving average of $2.20 and a 200-day simple moving average of $2.71. The company has a market cap of $50.07 million, a price-to-earnings ratio of -1.51 and a beta of 5.15. Titan Medical has a twelve month low of $1.05 and a twelve month high of $4.65.
Titan Medical (NASDAQ:TMDI) last released its earnings results on Wednesday, July 31st. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.89. As a group, analysts expect that Titan Medical will post -2.32 earnings per share for the current year.
About Titan Medical
Titan Medical Inc, a research and development stage company, focuses on the design, development, and commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery (MIS). The company is developing the SPORT Surgical System, a single-port robotic surgical system that comprises a surgeon-controlled patient cart, which includes a 3D vision system and multi-articulating instruments for performing MIS procedures; and a surgeon workstation that provides the surgeon with ergonomic interface to the patient cart and a 3D endoscopic view inside the patient's body during MIS procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Titan Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Medical and related companies with MarketBeat.com's FREE daily email newsletter.